Indications for use
As monotherapy in the treatment of:
- partial seizures with or without secondary generalization in adults and adolescents over 16 years of age with newly diagnosed epilepsy.
As part of additional therapy during treatment:
- partial seizures with or without secondary generalization in adults and children from 1 month with epilepsy;
- myoclonic seizures in adults and adolescents over 12 years of age with juvenile myoclonic epilepsy;
- primary generalized convulsive tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalized epilepsy.
Contraindications for use
Hypersensitivity to levetiracetam or other pyrrolidone derivatives, as well as to any components of the drug; impaired fructose tolerance; children up to 1 month of age (safety and effectiveness have not been established).
With caution: elderly patients (over 65 years old); liver diseases in the stage of decompensation; renal failure.
